- ►annals.org [PDF] LA Prosser, AA Stinnett, PA Goldman, LW … - Annals of Internal Medicine, 2000 - Am Coll Physicians Ann Intern Med. 2000;132:769-779. For author affiliations, current addresses,
and contributions, see end of text. S everal large-scale, long-term clinical
trials eval- uating statin drugs (3-hydroxy-3-methylglutaryl coenzyme A ... Cited by 188 - Related articles - BL Direct - All 6 versions
- ►annals.org [PDF] DA Ganz, KM Kuntz, GA Jacobson, J Avorn - Annals of internal medicine, 2000 - Am Coll Physicians David A. Ganz, BA; Karen M. Kuntz, ScD; Gretchen A. Jacobson, BA; and Jerry
Avorn, MD ... Background: 3-Hydroxy-3-methylglutaryl coenzyme A reductase
inhibitor (statin) therapy has proven efficacy in reducing the rate of ... Cited by 78 - Related articles - BL Direct - All 4 versions
VH Hamilton, FE Racicot, H Zowall, L Coupal, … - Jama, 1995 - health-economics.ca Rtiprmietl /ген J/W/i -й! Tfie Jouma.' aí ¡ne .tmericarc Medicai
Association Apr:! 5. 1ЭЭ5 Volume 273 CùpyiïùM 1B35. American Médica'
Association The Cost-effectiveness of HMG-CoA Reductase Inhibitors to ... Cited by 81 - Related articles - BL Direct - All 5 versions
J Tsevat, KM Kuntz, EJ Orav, MC Weinstein, … - American Heart Journal, 2001 - Elsevier Background The objective of this study was to assess the cost-effectiveness of
pravastatin therapy in survivors of myocardial infarction with average
cholesterol levels. Methods We performed a cost-effectiveness analysis ... Cited by 67 - Related articles - BL Direct - All 9 versions
- ►bmj.com DM Pickin, CJ McCabe, LE Ramsay, N Payne … - British Medical Journal, 1999 - heart.bmj.com The results of recent controlled trials with hydroxymethyl glutaryl coenzyme A
(HMG-CoA) reductase inhibitors (statins) 1-3 have radically altered attitudes to
cholesterol lowering treatment for the prevention of coronary heart disease ... Cited by 83 - Related articles - BL Direct - All 6 versions
- ►oxfordjournals.org [PDF] BA Van Hout, ML Simoons - European heart journal, 2001 - Eur Soc Cardiology Aims Treatment guidelines have been developed for both 'primary' and 'secondary'
prevention of coronary heart disease. These should consider both the efficacy as
well as the costs of such treatment, particularly the costs of treatment ... Cited by 57 - Related articles - BL Direct - All 5 versions
- ►bmj.com J Caro, W Klittich, A McGuire, I Ford, J Norrie, … - British Medical Journal, 1997 - bmj.com Prevention of coronary heart disease, the leading cause of death in the United
Kingdom, 1 2 is one of the primary goals of the NHS. 3 The West of Scotland
coronary prevention study 4 established that treating hypercholesterolaemia ... Cited by 147 - Related articles - BL Direct - All 6 versions
DM Huse, MW Russell, JD Miller, DF Kraemer, … - The American journal of cardiology, 1998 - Elsevier Currently, 6 hydroxymethylglutaryl coenzyme A (HMG-CoA) reductase inhibitors
(statins) are marketed in the United States (US). Given the wide variation in
the prices and efficacy of statins, formal cost-effectiveness analysis may ... Cited by 66 - Related articles - BL Direct - All 6 versions
- ►health-economics.ca [PDF] SA Grover, L Coupal, S Paquet, H Zowall - Archives of Internal Medicine, 1999 - Am Med Assoc Methods A validated model based on data from the Lipid Research Clinics cohort
was used to estimate the benefits and cost-effectiveness of lipid modification
with 3-hydroxy-3-methylglutaryl–coenzyme A reductase inhibitors (statins) ... Cited by 71 - Related articles - BL Direct - All 6 versions
L Goldman, MC Weinstein, PA Goldman, LW … - JAMA, 1991 - Am Med Assoc To determine the cost-effectiveness of HMG-CoA (3-hydroxy-3-methylglutaryl
coenzyme A) reductase inhibitors (such as lovastatin) for the primary and
secondary prevention of coronary heart disease, we used the Coronary Heart ... Cited by 327 - Related articles - All 3 versions
